title: Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim.
authors.affiliation: Department of Medicine, New York Medical College, Valhalla, NY, USA.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Arshad
authors.forename: Karen
authors.initials: K
authors.lastname: Seiter
authors.forename: Jaroslaw
authors.initials: J
authors.lastname: Bilaniuk
authors.forename: Anila
authors.initials: A
authors.lastname: Qureshi
authors.forename: Asawari
authors.initials: A
authors.lastname: Patil
authors.forename: Gita
authors.initials: G
authors.lastname: Ramaswamy
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
mesh_terms: D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D013161:Splenic Rupture / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000601:surgery; D014057:Tomography, X-Ray Computed
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim